...Inc. unit markets Dermagraft in the U.S. to treat full-thickness diabetic foot ulcers. Advanced BioHealing's TransCyte...

...Inc. unit markets Dermagraft in the U.S. to treat full-thickness diabetic foot ulcers. Advanced BioHealing's TransCyte...

...submit a supplement to the existing PMA in 1Q12. Advanced BioHealing's other approved product is TransCyte...

...fibroblast-derived skin substitute Dermagraft in the U.S. to treat full-thickness diabetic foot ulcers. The company's TransCyte...

...1Q12. FDA denied approval for Dermagraft to treat venous leg ulcers in 2005. The company's TransCyte...
...1997, but has yet to be marketed. Advanced BioHealing hopes to create arrangements to market TransCyte...
...Advanced Tissue Sciences Inc. and partner Smith & Nephew plc (LSE:SN; NYSE:SNN) developed Dermagraft and TransCyte...

...skin substitute Dermagraft in the U.S. to treat full-thickness diabetic foot ulcers. Another skin substitute, TransCyte...

...BioHealing markets two human fibroblast-derived skin substitutes: Dermagraft to treat full-thickness diabetic foot ulcers and TransCyte...

...it submitted the PMA in December 1996. The FDA approved the temporary covering version ( Dermagraft-TC...

...50-50 joint ventures focused on human-based tissue products, including Dermagraft for diabetic foot ulcers and TransCyte...

...Researchers presented data from 38 patients showing that TransCyte reduced the length of hospital stay by...
...American Burn Association meeting in Orlando. Advanced Tissue Sciences Inc. (ATIS), La Jolla, Calif. Product: TransCyte...